Physician profile
Christopher K Holt
NPI 1164570206
$2,424.81
in general payments reported to CMS, 2019-2025
23 companies · $459 in 2025
The $459 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $152 · 2021: $266 · 2022: $501 · 2023: $427 · 2024: $377 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.71 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $390.81 | 2021-2025 | Rocklatan, Tryptyr, Eysuvis |
| Abbvie INC. | $294.00 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $259.03 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $200.98 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.82 | 2019-2021 | |
| Oyster Point Pharma, INC. | $123.56 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $97.48 | 2020-2022 | |
| Johnson & Johnson Vision Care, INC. | $93.81 | 2021-2023 | Acuvue |
| Amgen INC. | $75.95 | 2024-2025 | Tepezza |
| Coopervision INC. | $72.67 | 2022-2024 | Myday Contact Lens, Clariti Contact Lens |
| Aerie Pharmaceuticals, INC. | $71.71 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $70.66 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $70.54 | 2025 | |
| Glaukos Corporation | $68.95 | 2022 | |
| Kala Pharmaceuticals, INC. | $58.91 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $58.01 | 2022-2023 | Acthar |
| Shire North American Group INC | $56.11 | 2019 | |
| Horizon Therapeutics Plc | $40.83 | 2023 | Tepezza |
| Thea Pharma INC. | $40.72 | 2023-2024 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $39.03 | 2019 | |
| Eyevance Pharmaceuticals LLC | $27.13 | 2022-2023 | Flarex |
| Omeros Corporation | $20.52 | 2021 | |
| New World Medical,INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.